866-997-4948(US-Canada Toll Free)

B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Apr 2014

Category :

Oncology

No. of Pages : 96 Pages

This report provides comprehensive information on the therapeutic development for B-Cell Chronic Lymphocytic Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Chronic Lymphocytic Leukemia and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of B-Cell Chronic Lymphocytic Leukemia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for B-Cell Chronic Lymphocytic Leukemia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the B-Cell Chronic Lymphocytic Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the B-Cell Chronic Lymphocytic Leukemia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for B-Cell Chronic Lymphocytic Leukemia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding B-Cell Chronic Lymphocytic Leukemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents

Table of Contents 2

List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
B-Cell Chronic Lymphocytic Leukemia Overview 9
Therapeutics Development 10
Pipeline Products for B-Cell Chronic Lymphocytic Leukemia - Overview 10
Pipeline Products for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis 11
B-Cell Chronic Lymphocytic Leukemia - Therapeutics under Development by Companies 12
B-Cell Chronic Lymphocytic Leukemia - Therapeutics under Investigation by Universities/Institutes 15
B-Cell Chronic Lymphocytic Leukemia - Pipeline Products Glance 17
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
B-Cell Chronic Lymphocytic Leukemia - Products under Development by Companies 20
B-Cell Chronic Lymphocytic Leukemia - Products under Investigation by Universities/Institutes 21
B-Cell Chronic Lymphocytic Leukemia - Companies Involved in Therapeutics Development 22
Biogen Idec Inc. 22
rEVO Biologics 23
Nippon Shinyaku Co., Ltd. 24
Ono Pharmaceutical Co., Ltd. 25
Immunomedics, Inc. 26
MABLife S.A.S 27
SBI Biotech Co., Ltd. 28
Neopharm Ltd. 29
Advancell 30
Vivia Biotech, S.L. 31
AbbVie Inc. 32
BioNovion B.V. 33
TheraMAB LLC. 34
B-Cell Chronic Lymphocytic Leukemia - Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Combination Products 36
Assessment by Target 37
Assessment by Mechanism of Action 40
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
acadesine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
bafetinib - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
rituximab - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Allogeneic CD19CAR-TCM cells - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
FBTA-05 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
CD19.CAR-CD28Z T Cells - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
CD19 Specific T Cell - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
GNKG-168 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
ilorasertib - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
ONO-4059 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Allogeneic Cell Therapy + Tumor-Derived Lymphocytes - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Gene Modified T Cells for Leukemia - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
TG-20 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
MAT-304 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Vivia-009 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Monoclonal Antibody Targeting APRIL - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
alemtuzumab biosimilar - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
GNKS-356 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
TAB-08 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Central Memory T Cell Therapy For Cancer - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
202-b - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Xanthone Derivatives For Cancer - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
alemtuzumab biosimilar - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
B-Cell Chronic Lymphocytic Leukemia - Recent Pipeline Updates 80
B-Cell Chronic Lymphocytic Leukemia - Dormant Projects 84
B-Cell Chronic Lymphocytic Leukemia - Discontinued Products 85
B-Cell Chronic Lymphocytic Leukemia - Product Development Milestones 86
Featured News & Press Releases 86
Dec 10, 2013: Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell Malignancies 86
Dec 07, 2013: Seattle Genetics Presents Data from Novel Antibody-Drug Conjugate SGN-CD19A at ASH 2013 90
Aug 24, 2012: TG Therapeutics Announces Poster Presentation For Ublituximab At 7th International Workshop On Waldenstrom\'s Macroglobulinemia 92
Dec 12, 2011: CytRx Announces Presentation Of Favorable Phase II Results With Bafetinib In Relapsed B-Cell Chronic Lymphocytic Leukemia At ASH Conference 93
Nov 15, 2011: TheraMAB launches Phase I clinical trial of first-in-class agonistic monoclonal antibody TAB08 in Russia 94

Appendix 95
Methodology 95
Coverage 95
Secondary Research 95
Primary Research 95
Expert Panel Validation 95
Contact Us 96
Disclaimer 96

List of Table


Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H1 2014 10
Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 13
Number of Products under Development by Companies, H1 2014 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2014 16
Comparative Analysis by Clinical Stage Development, H1 2014 17
Comparative Analysis by Early Stage Development, H1 2014 18
Comparative Analysis by Unknown Stage Development, H1 2014 19
Products under Development by Companies, H1 2014 20
Products under Investigation by Universities/Institutes, H1 2014 21
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Biogen Idec Inc., H1 2014 22
B-Cell Chronic Lymphocytic Leukemia - Pipeline by rEVO Biologics, H1 2014 23
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Nippon Shinyaku Co., Ltd., H1 2014 24
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2014 25
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Immunomedics, Inc., H1 2014 26
B-Cell Chronic Lymphocytic Leukemia - Pipeline by MABLife S.A.S, H1 2014 27
B-Cell Chronic Lymphocytic Leukemia - Pipeline by SBI Biotech Co., Ltd., H1 2014 28
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Neopharm Ltd., H1 2014 29
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Advancell, H1 2014 30
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Vivia Biotech, S.L., H1 2014 31
B-Cell Chronic Lymphocytic Leukemia - Pipeline by AbbVie Inc., H1 2014 32
B-Cell Chronic Lymphocytic Leukemia - Pipeline by BioNovion B.V., H1 2014 33
B-Cell Chronic Lymphocytic Leukemia - Pipeline by TheraMAB LLC., H1 2014 34
Assessment by Monotherapy Products, H1 2014 35
Assessment by Combination Products, H1 2014 36
Number of Products by Stage and Target, H1 2014 39
Number of Products by Stage and Mechanism of Action, H1 2014 42
Number of Products by Stage and Route of Administration, H1 2014 45
Number of Products by Stage and Molecule Type, H1 2014 47
B-Cell Chronic Lymphocytic Leukemia Therapeutics - Recent Pipeline Updates, H1 2014 80
B-Cell Chronic Lymphocytic Leukemia - Dormant Projects, H1 2014 84
B-Cell Chronic Lymphocytic Leukemia - Discontinued Products, H1 2014 85

List of Chart


Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H1 2014 10
Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 15
Comparative Analysis by Clinical Stage Development, H1 2014 17
Comparative Analysis by Early Stage Products, H1 2014 18
Assessment by Monotherapy Products, H1 2014 35
Number of Products by Top 10 Target, H1 2014 37
Number of Products by Stage and Top 10 Target, H1 2014 38
Number of Products by Top 10 Mechanism of Action, H1 2014 40
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 41
Number of Products by Top 10 Route of Administration, H1 2014 44
Number of Products by Stage and Top 10 Route of Administration, H1 2014 45
Number of Products by Top 10 Molecule Type, H1 2014 46
Number of Products by Stage and Top 10 Molecule Type, H1 2014 47

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *